Extending peptide half-life
A peptide that binds tightly and does nothing in an animal has usually been cleared rather than out-competed. Two processes dominate, and they need different fixes, so the first job is deciding which one is limiting.
The two clearance routes
Glomerular filtration removes molecules below roughly five kilodaltons, which covers almost every peptide, at a rate set largely by hydrodynamic size and charge. Nothing about sequence chemistry prevents this. The only defense is to increase apparent size.
Proteolysis cuts the peptide in circulation and at tissue surfaces. Exopeptidases trimming from either terminus account for much of it, with endopeptidases cutting internally.
A plasma stability assay distinguishes them. If the peptide survives hours in plasma and still has a circulating half-life of minutes, filtration is limiting and backbone chemistry will not help. If it disappears in plasma within minutes, fix the proteolysis first, because there is no point enlarging a molecule that is being chopped up.
Fixing proteolysis
Terminal capping is cheap and effective. N-terminal acetylation blocks aminopeptidases and C-terminal amidation blocks carboxypeptidases, and both are routine in synthesis. Amidation also removes a negative charge, which sometimes helps potency and sometimes hurts it.
Substituting the terminal residues with their D enantiomers achieves the same blockade while keeping the free terminus, and often costs little affinity because terminal residues are frequently peripheral to the interface.
For internal cleavage, identify the site from the plasma fragments and then N-methylate the scissile amide, substitute a D residue, or bridge across it. Head-to-tail cyclization removes both exopeptidase routes at once and is the strongest single move where the termini are not part of the binding site.
Increasing apparent size
Lipidation attaches a fatty acid, usually a C16 palmitoyl or a C18 diacid, through a short spacer. The lipid binds reversibly to serum albumin, and the peptide then circulates as part of a sixty-seven kilodalton complex that filtration ignores. This is the approach behind the long-acting GLP-1 agonists, and the C18 diacid with a glutamate and short PEG spacer is close to a solved design. It is the first thing to try: the modification is small, it is made on resin, and the potency cost is usually modest.
PEGylation attaches a polyethylene glycol chain, typically twenty to forty kilodaltons, which raises hydrodynamic radius far beyond the filtration cutoff. It works reliably and it usually costs potency, because the polymer shields the binding surface as well as the protease. Site-specific attachment away from the interface limits that. PEG also accumulates in tissue with repeated dosing and anti-PEG antibodies are now well documented, which has cooled enthusiasm for it in chronic indications.
Albumin binding can be achieved without lipid, using a small albumin-binding domain or a peptide that binds albumin directly. It gives similar exposure to lipidation with a different chemistry.
Fc fusion puts the peptide on an antibody Fc, which adds filtration resistance and recycling through the neonatal Fc receptor, giving half-lives measured in days to weeks. It moves the molecule into recombinant manufacture and into the size range where tissue penetration suffers, so it fits chronic systemic targets rather than anything needing tissue access.
Choosing, and what it costs
Match the extension to the dosing interval you need. Terminal capping alone buys hours. Lipidation buys daily to weekly dosing. Fc fusion buys weeks and changes the manufacturing route entirely.
Expect to pay in potency and check it every time. A lipid or polymer near the binding face will cost affinity, so attachment point selection is design work rather than a chemistry default, and a short scan of positions is usually worth running.
Expect solubility to change, usually downward for lipidation and upward for PEGylation, and re-run the formulation work rather than assuming the parent conditions carry over.
Confirm the modification is where you intended by peptide mapping. A conjugate characterized only by intact mass tells you something was attached and not where.